#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug trials
Pembrolizumab 441
Sodium Chloride 403
Carboplatin 329
Cisplatin 274
Paclitaxel 245
Fluorouracil 226
Oxaliplatin 218
Nivolumab 205
Dexamethasone 203
Rituximab 189
Cyclophosphamide 183
Durvalumab 157
Bevacizumab 157
Paracetamol 154
Capecitabine 152
Atezolizumab 145
Docetaxel 127
Prednisone 125
Tocilizumab 120
Prednisolone 116
Gemcitabine 114
Venetoclax 113
Etoposide 113
Mycophenolate Mofetil 111
Pemetrexed 109
Doxorubicin Hydrochloride 104
Lenalidomide 97
Infliximab 93
Ipilimumab 89
Acetylsalicylic Acid 87
Folinic Acid 87
Semaglutide 86
Placebo 83
Paclitaxel Albumin-Bound 81
Methotrexate 77
Cytarabine 77
Daratumumab 77
Fludarabine Phosphate 75
Calcium Folinate 74
Letrozole 73
Bortezomib 70
Olaparib 70
Gemcitabine Hydrochloride 68
Dapagliflozin 66
Obinutuzumab 65
Trastuzumab 65
Azacitidine 65
Fulvestrant 62
Cetuximab 61
Tacrolimus 61
Methylprednisolone 61
Lenvatinib 60
Irinotecan 58
Irinotecan Hydrochloride Trihydrate 58
Vincristine Sulfate 57
Temozolomide 56
Cemiplimab 54
Trastuzumab Deruxtecan 53
Enzalutamide 51
Apixaban 49
Dexamethasone Sodium Phosphate 49
Codeine Phosphate 48
Betamethasone Sodium Phosphate 48
Lidocaine Hydrochloride Monohydrate 47
Exemestane 47
Buclizine Hydrochloride 46
Anastrozole 46
Potassium Chloride 46
Empagliflozin 46
Hydrocortisone 45
Lidocaine Hydrochloride 45
Amoxicillin 44
Ribociclib 44
Doxorubicin 43
Pertuzumab 43
Adalimumab 43
Clopidogrel 42
Ruxolitinib 41
Tenofovir Alafenamide 41
Rivaroxaban 41
Abemaciclib 41
Ibrutinib 40
Oxygen 40
Pomalidomide 40
Clavulanic Acid 39
Atorvastatin 39
Ropivacaine Hydrochloride 39
Metformin Hydrochloride 39
Ifosfamide 38
Carfilzomib 38
Palbociclib 38
Propofol 38
Bendamustine Hydrochloride 38
Emtricitabine 37
Acalabrutinib 37
Dostarlimab 37
Cyclophosphamide Monohydrate 37
Pemetrexed Disodium 37
Dexamethasone Phosphate 36
Sulfamethoxazole 36

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 AZD0120

Clinical trials are investigating AZD0120 in people with relapsed or refractory multiple myeloma, a cancer that has returned or no longer responds to treatment.

1 week ago
#2 STREPTOCOCCUS VIRIDANS

Clinical trials investigating "STREPTOCOCCUS VIRIDANS" are studying whether a related study treatment can reduce respiratory infections in children.

1 week ago
#3 STREPTOCOCCUS PYOGENES

Clinical trials investigating STREPTOCOCCUS PYOGENES are studying a treatment called PMBL (Ismigen) in children with respiratory tract infections.

1 week ago
#4 AZD1163

Clinical trials are investigating AZD1163 in adults with moderately to severely active rheumatoid arthritis.

1 week ago
#5 AZD5335

Clinical trials are investigating AZD5335 in women with advanced platinum-resistant epithelial ovarian cancer.

1 week ago
#6 IMB 101

Clinical trials are studying NAV-240 in adults with moderate-to-severe hidradenitis suppurativa.

1 week ago

Drugs starting by g

  • 2 

    Gskvx000000008885

    ,

    Clinical trials are underway to evaluate the safety, efficacy, and immune response of GSKVX000000008885, a novel therapeutic vaccine for chronic hepatitis B (CHB). This vaccine is being tested in combination with other treatments in patients who are already on nucleos(t)ide analogue (NA) therapy. The trials aim to assess the potential of this vaccine to improve outcomes for CHB patients by targeting the hepatitis B virus (HBV) and boosting the immune response against it.

    Related diseases and areas:

  • 2 

    Gskvx000000009151

    ,

    This article discusses clinical trials investigating the use of GSKVX000000009151, a novel therapeutic vaccine, for the treatment of chronic hepatitis B (CHB). The trials aim to evaluate the safety, efficacy, and immune response of this vaccine in combination with other treatments in patients with CHB who are already on nucleos(t)ide analogue (NA) therapy.

    Related diseases and areas:

  • 1 

    Gskvx000000014593

    ,

    This article discusses the clinical trials of GSK’s Herpes Zoster vaccine, known as GSKVx000000014593, in immunocompromised children aged 1-17 who have received kidney transplants. The study aims to assess the safety, reactogenicity, and immune response of this vaccine in this specific patient population. The trials are designed to evaluate the vaccine’s potential in preventing Herpes Zoster (shingles) in these vulnerable children.

    Related diseases and areas:

  • 2 

    Gskvx000000017033

    ,

    This article discusses clinical trials investigating the use of GSKVx000000017033, a novel drug candidate, for the treatment of chronic hepatitis B. The trials aim to assess the safety, efficacy, and immune response of this drug when used alone or in combination with other therapies in patients with chronic hepatitis B who are already on nucleos(t)ide analogue therapy.

    Related diseases and areas:

  • 1 

    GSKVX000000017986

    ,

    Clinical trials are studying GSKVX000000017986 as part of meningococcal vaccine research. These studies look at safety, side effects after vaccination, and immune response in healthy participants. The trial data here focuses on different vaccine formulations and comparisons with other vaccines.

    Related diseases and areas:

  • 5 

    GSKVX000000025896

    ,

    Clinical trials are investigating GSKVX000000025896 in healthy children, mainly to study a chickenpox (varicella) vaccine. These studies look at immune response, safety, and how the vaccine performs compared with marketed vaccines in children aged 12 to 15 months and 4 to 6 years.

    Related diseases and areas:

  • 1 

    GSKVX000000030810

    ,

    Clinical trials are investigating GSKVX000000030810 in people with herpes simplex, including healthy adults and adults with recurrent genital herpes. These studies look at safety, local and whole-body reactions, immune response, and whether the study treatment can reduce herpes episodes. The trials are in Phase 1/2.

    Related diseases and areas:

  • 1 

    GSKVX000000030825

    ,

    Clinical trials are studying GSKVX000000030825 in people with herpes simplex and in healthy adults. These studies look at safety, side effects after each dose, immune response, and whether the treatment can help prevent recurrent genital herpes. The trials include healthy participants aged 18-40 years and participants aged 18-60 years with recurrent genital herpes.

    Related diseases and areas:

  • 1 

    GSKVX000000030918

    ,

    Clinical trials are studying GSKVX000000030918 in people with herpes simplex. These studies look at safety, side effects, immune response, and whether the treatment can help prevent recurrent genital herpes. The trials include healthy adults and adults with recurrent genital herpes.

    Related diseases and areas:

  • 1 

    GSKVX000000034792

    ,

    Clinical trials are studying GSKVX000000034792 in healthy younger and older adults to find and confirm a dose and to assess safety, reactogenicity, and immune response. The trial also compares immune responses after vaccination. These studies help researchers understand how the vaccine performs in prevention of influenza infection.

    Related diseases and areas:

  • 3 

    GSKVX000000034794

    ,

    Clinical trials are investigating GSKVX000000034794 in influenza vaccine studies. These trials look at immune response, safety, and reactogenicity in healthy adults and adults 18 years and older. The studies compare different vaccine versions and measure how well they work and how well they are tolerated.

    Related diseases and areas:

  • 1 

    GSKVX000000034795

    ,

    Clinical trials are investigating GSKVX000000034795 as part of influenza vaccine research in healthy younger and older adults. These studies look at safety, reactogenicity, and immune response, including dose finding and confirmation. The main goal is to see how well the vaccine works in people who do not have influenza infection.

    Related diseases and areas:

  • 1 

    GSKVX000000034796

    , ,

    Clinical trials are investigating GSKVX000000034796 as part of influenza vaccine research in healthy younger and older adults. These studies aim to find and confirm the dose and assess safety, reactogenicity, and immune response. The target population is healthy volunteers taking part in prevention studies for influenza infection.

    Related diseases and areas:

  • 1 

    GSKVX000000034797

    ,

    Clinical trials are investigating GSKVX000000034797 as part of an influenza vaccine study in healthy younger and older adults. The trial is looking at safety, reactogenicity, and immune response, and it compares study vaccine groups with licensed flu vaccines.

    Related diseases and areas:

  • 3 

    GSKVX000000034798

    ,

    Clinical trials are investigating GSKVX000000034798 as part of influenza vaccine studies in healthy adults and adults 18 years and older. These trials look at safety, reactogenicity, and immune response, with some also comparing GSKVX000000034798 to other influenza vaccines. The studies include Phase 1/2 and Phase 2 research.

    Related diseases and areas:

  • 1 

    GSKVX000000039711

    ,

    Clinical trials are investigating GSKVX000000039711 as part of an influenza vaccine study in healthy younger and older adults. The trials aim to assess safety, reactogenicity, and immune response, including dose finding and confirmation.

    Related diseases and areas:

  • 1 

    GSKVX000000040033

    ,

    Clinical trials are investigating GSKVX000000040033 as part of an influenza vaccine study in healthy younger and older adults. The trials aim to find and confirm the dose, and to assess safety, reactogenicity, and immune response. They include healthy volunteers and are designed to compare different vaccine options.

    Related diseases and areas:

  • 1 

    GSKVX000000044501

    ,

    Clinical trials are investigating GSKVX000000044501 in a candidate vaccine study for urinary tract infections. These trials look at safety, immune response, and whether it can help prevent new E. coli UTIs in adults, especially females aged 18 to 64 years.

    Related diseases and areas:

  • 1 

    GSKVX000000046019

    ,

    Clinical trials are investigating GSKVX000000046019 as a candidate vaccine for urinary tract infections (UTIs). The studies aim to check safety, immune response, and whether it can help prevent new E. coli UTIs in adults, especially females aged 18 to 64 years.

    Related diseases and areas:

  • 3 

    GSKVX000000048110

    , ,

    Clinical trials investigating GSKVX000000048110 are studying influenza vaccines in adults, including healthy younger and older adults and adults 18 years and older. These trials look at immune response, safety, and reactogenicity, which means how often side effects happen after vaccination. The studies are in Phase 1/2 and Phase 2.

    Related diseases and areas:

  • 3 

    GSKVX000000048111

    , ,

    Clinical trials are investigating GSKVX000000048111 in studies of influenza vaccines for adults and healthy volunteers. These trials look at immune response, safety, and reactogenicity, which means how often short-term side effects happen after vaccination. The studies include Phase 1/2 and Phase 2 trials in adults 18 years and older.

    Related diseases and areas:

  • 2 

    GSKVX000000070248

    ,

    Clinical trials are investigating GSKVX000000070248 as part of influenza vaccine studies in adults 18 years and older. These trials look at immune response, safety, and reactogenicity, which means how often short-term reactions happen after vaccination. They compare different study vaccine groups and other influenza vaccines.

  • 2 

    GSKVX000000070250

    ,

    Clinical trials are studying GSKVX000000070250 in adults 18 years and older with influenza-related vaccination research. These studies look at immune response, safety, and reactogenicity, which means how often short-term reactions happen after vaccination.

  • 1 

    GSKVX000000070965

    ,

    Clinical trials are studying GSKVX000000070965 in adults 18 years and older. These trials aim to measure immune response, safety, and reactogenicity, which means how often short-term side effects happen after vaccination. The study is for people with influenza, human.

  • 1 

    GT-002

    ,

    Clinical trials are investigating GT-002 in people with schizophrenia spectrum disorders. The TOTEMS study is looking at short-term effects on brain and body response measures, including signs linked to cognitive problems. It aims to compare GT-002 with placebo and oxazepam in adults who meet specific psychosis-related diagnoses.

    Related diseases and areas:

  • 1 

    Gt005

    ,

    Clinical trials are investigating Gt005 in people with geographic atrophy, a form of vision loss linked to age-related macular degeneration. The study data focus on long-term safety, especially in participants who already received Gt005 in earlier Gyroscope studies. The main goal is to see how safe the treatment is over time.

    Related diseases and areas:

  • 1 

    Gtaexs617

    ,

    Clinical trials are investigating Gtaexs617 in people with advanced solid tumors. This article explains what the study is trying to learn, including safety, tolerability, and early anti-tumor activity. It also covers the study phase, who may take part, and the main outcomes being measured.

    Related diseases and areas:

  • 1 

    GUAIACOL

    Clinical trials investigating GUAIACOL are evaluating treatment strategies in people with breast cancer, especially triple negative breast cancer and hormone receptor-low positive/HER2 negative breast cancer. These studies are looking at how well the tested treatments work before surgery and how they affect survival outcomes.

    Related diseases and areas:

  • 2 

    Guanabenz Acetate

    ,

    Clinical trials investigating Guanabenz Acetate are studying its safety and possible benefit in Vanishing White Matter, a rare brain disorder. The trials focus on pediatric patients and children with early childhood onset disease, including a long-term extension study.

    Related diseases and areas:

  • 1 

    Guanfacine

    ,

    Clinical trials investigating Guanfacine are studying its safety and effectiveness in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). The main focus is long-term treatment in patients aged 6 to 17 years, especially when stimulants are not suitable, not tolerated, or not effective.

    Related diseases and areas:

  • 26 

    Guselkumab

    , , , , ,

    Clinical trials are investigating Guselkumab in several immune-mediated diseases, including Crohn’s disease, ulcerative colitis, psoriatic arthritis, psoriasis, and pouchitis. These studies look at how well it works, how safe it is, and how it performs in adults and children, often compared with placebo or other treatments.

    Related diseases and areas:

  • 1 

    GVV858

    ,

    Clinical trials are investigating GVV858 in people with advanced HR+/HER2- breast cancer and other advanced solid tumors. These studies look at safety, tolerability, and the best dose range, and they also test GVV858 alone or with endocrine therapy. The main phase is Phase 1/2.

    Related diseases and areas:

  • 1 

    GXV813

    ,

    Clinical trials are studying GXV813 in hospitalized adults with schizophrenia. These studies aim to assess safety, tolerability, and treatment response, especially in people with an acute episode. The current trial is in Phase 2 and compares GXV813 with placebo.

    Related diseases and areas: